Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

Nischal Ranganath, John C. O'Horo, Douglas W. Challener, Sidna M. Tulledge-Scheitel, Marsha L. Pike, Michael O'Brien, Raymund R. Razonable, Aditya Shah

Research output: Contribution to journalArticlepeer-review

Abstract

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.

Original languageEnglish (US)
Pages (from-to)E537-E539
JournalClinical Infectious Diseases
Volume76
Issue number3
DOIs
StatePublished - Feb 1 2023

Keywords

  • COVID-19
  • paxlovid
  • rebound phenomenon
  • therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons'. Together they form a unique fingerprint.

Cite this